SYNTERA BIORISK
SpeciesPoultry & birdsReleaseNetherlands · 2026-09-07
  1. Global Overview
  2. Europe
  3. Netherlands
  4. Highly pathogenic avian influenza
Country–disease dossierNetherlands · Highly pathogenic avian influenza
View economic evidence Run scenarioCompare interventionsInspect BCR assumptions Vaccine & intervention marketTrade analysis
Netherlands cross-disease portfolio NETHERLANDS DISEASE PROFILE · LINKED WORKSPACE

Highly pathogenic avian influenza

Official evidence, 12-province exposure and transparent national planning economics.

Profile readyEvidence + editable CBA
African swine fevernot present external incursion riskHighly pathogenic avian influenzacurrent 2026 infected holdingsBluetonguerecent epidemic no new 2025 detectionsBovine tuberculosisofficially free with residual import riskFoot-and-mouth diseaseofficially free without vaccinationPeste des petits ruminantsofficially freeNewcastle diseasecompulsory preventive vaccinationClassical swine feverofficially freeSheep pox and goat poxno current domestic event external incursion preparednessLumpy skin diseasefree status under external incursion pressureBovine viral diarrhoeaendemic control transitionJohne’s diseaseendemic quality assurance programmeEpizootic haemorrhagic diseasenotifiable no current domestic event in registered source
Official disease status · 2026-07-17

Highly pathogenic avian influenza

Twenty infected or culled kept-bird locations are listed for 2026 through 17 July; the national risk was assessed as low to moderate when the housing order ended on 11 June.

Selected geography
Netherlands
Susceptible livestock
87.72m
Evidence nature
Observed / official
Exposure layer

Netherlands · susceptible livestock

PDOK BRK 2026
Exposure is livestock inventory—not inferred prevalence. Regional selection updates supported evidence; the CBA remains explicitly national because regional cost evidence is unavailable.
Validated exposure

Netherlands

Gallus poultry87.72m

CBS 80783ENG · 2025 final observations; source grain retained.

Official signal at selected grain
  • 2026 listed infected or culled locations through 17 July20 locations
Observed economics · national/source scope
Observed direct loss · national
N/A
Published programme cost · source scope
€9.999m HPAI control expenditure
Monetised trade effect
N/A

No compatible current Netherlands-specific direct-loss estimate is registered; no value is inferred.

Relevant wildlife & interface

Wildlife evidence

No compatible current national wildlife-population layer is registered.

Population denominators remain unavailable unless explicitly registered; qualitative host evidence is not converted into a count.
ILLUSTRATIVE

Illustrative scenario—country-specific intervention evidence unavailable.

The planning parameters are retained, but the BCR is not estimated in this public profile.

Open Impact CalculatorWhy these assumptions?
Control choices

Default option scenarios

  1. 01Farm and wild-bird surveillancePlanning option retained for explicit activation in Scenario Lab
  2. 02Targeted vaccination readinessPlanning option retained for explicit activation in Scenario Lab
  3. 03Rapid culling and zoningPlanning option retained for explicit activation in Scenario Lab
Trade & movement

Documented consequence

Infected premises are culled and protection or surveillance zones restrict movements; national housing measures vary with assessed risk.

Registered sources document controls but not a compatible Netherlands-wide monetised consequence.
Evidence register

5 sources used in this view

Release principle: every Netherlands disease has a complete decision workspace. Missing observed economics stay visible as N/A; modelled planning values are separately labelled, editable and never presented as evidence.
Sustainability & One HealthCountry-specific GHG, AMU/AMR and biodiversity results remain withheld until compatible evidence is registered; none is inferred from the disease profile.
Request complete Decision Brief